Insmed Incorporated INSM
114.41 USD +5.64 (+5.19%)
At closeNov 9, 2026, 5:56 AM EST
115.88 +1.47 +1.29%
Pre-market · Nov 9, 5:56 AM ET
107.29 Day range 114.65
90.39 52-week range 212.75
- YTD
- -34.27%
- 1 year
- -38.39%
News
seekingalpha.com Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales…
247wallst.com Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades…
benzinga.com HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220 HC Wainwright & Co. analyst Matthew Caufield assumes Insmed (NASDAQ:INSM) with a Buy rating and announces Price Target of $220.
prnewswire.com Insmed to Present at November and December 2026 Investor Conferences BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform…
benzinga.com Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201 Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate Insmed (NASDAQ:INSM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 73.71 percent increase over losses of $(1.75) per…
benzinga.com Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.700 billion-$1.870 billion to $1.810 billion-$1.870 billion vs $1.801 billion estimate.
benzinga.com $100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.42% on an annualized basis producing an average annual return of 24.03%. Currently, Insmed has a market capitalization of…
benzinga.com Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213 Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
benzinga.com This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
benzinga.com This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
benzinga.com HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.